Japan’s largest drugmaker Takeda (announced new Phase III data for zasocitinib, its investigational, next-generation, highly ...
UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results